Monthly information on share capital and company voting rights
07 Avril 2022 - 10:30PM
Monthly information on share capital and company voting rights
Listing market: Euronext GrowthISIN code:
FR0010425595
Date |
Total number of sharesin the
capital |
Total number of voting rights |
03/31/2022 |
45,490,810 |
51,083,431 |
About Cellectis
Cellectis is a clinical-stage biotechnology
company using its pioneering gene-editing platform to develop
life-saving cell and gene therapies. Cellectis utilizes an
allogeneic approach for CAR-T immunotherapies in oncology,
pioneering the concept of off-the-shelf and ready-to-use
gene-edited CAR T-cells to treat cancer patients, and a platform to
make therapeutic gene editing in hemopoietic stem cells for various
diseases. As a clinical-stage biopharmaceutical company with over
22 years of expertise in gene editing, Cellectis is developing
life-changing product candidates utilizing TALEN®, its gene editing
technology, and PulseAgile, its pioneering electroporation system
to harness the power of the immune system in order to treat
diseases with unmet medical needs. As part of its commitment to a
cure, Cellectis remains dedicated to its goal of providing
lifesaving UCART product candidates for multiple cancers including
acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia
(B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing
on hemopoietic stem cells to treat blood disorders,
immunodeficiencies and lysosomal storage diseases. Cellectis’
headquarters are in Paris, France, with locations in New York, New
York and Raleigh,North Carolina. Cellectis is listed on the Nasdaq
Global Market (ticker: CLLS) and on Euronext Growth (ticker:
ALCLS).
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.For more
information, visit www.cellectis.comFollow Cellectis on social
media: @cellectis, LinkedIn and YouTube.
For further information, please
contact: Media
contacts: Pascalyne
Wilson, Director, Communications, +33 (0)7 76 99 14 33,
media@cellectis.comMargaret Gandolfo, Senior Manager,
Communications, +1 (646) 628 0300
Investor Relation contact: Arthur Stril,
Chief Business Officer, +1 (347) 809 5980,
investors@cellectis.com Ashley R. Robinson, LifeSci Advisors,
+1 617 430 7577
Forward-looking Statements
This press release contains “forward-looking”
statements within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by words such as
“anticipate,” “believe,” “intend”, “expect,” “plan,” “scheduled,”
“could” and “will,” or the negative of these and similar
expressions. These forward-looking statements, which are based on
our management’s current expectations and assumptions and on
information currently available to management. Forward-looking
statements include statements about the timing of our presentation
of data and submission of regulatory filings, the adequacy of our
supply of clinical vials, the operational capabilities at our
manufacturing facilities, and the sufficiency of cash to fund
operation. These forward-looking statements are made in light of
information currently available to us and are subject to numerous
risks and uncertainties, including with respect to the numerous
risks associated with biopharmaceutical product candidate
development as well as the duration and severity of the COVID-19
pandemic and governmental and regulatory measures implemented in
response to the evolving situation. With respect to our cash
runway, our operating plans, including product development plans,
may change as a result of various factors, including factors
currently unknown to us. Furthermore, many other important factors,
including those described in our Annual Report on Form 20-F and the
financial report (including the management report) for the year
ended December 31, 2021 and subsequent filings Cellectis makes with
the Securities Exchange Commission from time to time, as well as
other known and unknown risks and uncertainties may adversely
affect such forward-looking statements and cause our actual
results, performance or achievements to be materially different
from those expressed or implied by the forward-looking statements.
Except as required by law, we assume no obligation to update these
forward-looking statements publicly, or to update the reasons why
actual results could differ materially from those anticipated in
the forward-looking statements, even if new information becomes
available in the future.
- Voting_Rights_PR_March_EN_docx
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Cellectis Nom Eo 05 (EU:ALCLS)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024